Clinical data from patients with DLBCL
| . | APRIL high . | APRIL low . |
|---|---|---|
| Disease stage* | ||
| I, n | 1 | 2 |
| II, n | 1 | 2 |
| III/IV, n | 4 | 4 |
| Serum LDH level† | ||
| High, n | 5 | 6 |
| Low, n | 3 | 2 |
| Proliferation index, mean ± SD‡ | 75 ± 8 (n = 22) | 68 ± 19 (n = 25) |
| DLBCL type§ | ||
| GC, n | 19 | 17 |
| Activated, n | 17 | 10 |
| Age, y, mean ± SD | 61 ± 19 (n = 26) | 57 ± 8 (n = 30) |
| . | APRIL high . | APRIL low . |
|---|---|---|
| Disease stage* | ||
| I, n | 1 | 2 |
| II, n | 1 | 2 |
| III/IV, n | 4 | 4 |
| Serum LDH level† | ||
| High, n | 5 | 6 |
| Low, n | 3 | 2 |
| Proliferation index, mean ± SD‡ | 75 ± 8 (n = 22) | 68 ± 19 (n = 25) |
| DLBCL type§ | ||
| GC, n | 19 | 17 |
| Activated, n | 17 | 10 |
| Age, y, mean ± SD | 61 ± 19 (n = 26) | 57 ± 8 (n = 30) |
LDH indicates lactate dehydrogenase; GC, germinal center.
Disease stage was defined according to the Ann Arbor staging system.
Serum LDH level was determined by standard techniques.
The proliferation index was determined by Ki-67 in situ staining.
The DLBCL type was defined in IHC with the combination of CD10, bcl-6, and IRF-4 markers as reported recently by Hans et al.46